The Acton, Massachusetts–based automated insulin delivery technology developer yesterday evening posted losses of $35 million, or 50¢ per share, on sales of $299.4 million for the three months ended June 30, 2022, for a $10 million bottom-line slide deeper into the red on sales growth of 13.8%
Get the full story at our sister site, Drug Delivery Business News.